Market Place
Sourcing Support
MaaT Pharma Announces 2025 Annual Results & Business Updates
31 Mar 2026 //
BUSINESSWIRE
Maat Pharma Reports Monthly Voting Rights And Share Capital
03 Feb 2026 //
PHARMIWEB
Maat Pharma Initiates IMMUNOLIFE Phase 2 Study On Gut Microbiome
20 Jan 2026 //
BUSINESSWIRE
Maat Pharma Unveils ARES Ph 3 Data For MaaT013 In Acute GvHD
08 Dec 2025 //
BUSINESSWIRE
Maat Pharma Shows Maat034`s Immune Activation at SITC Meeting
05 Nov 2025 //
BUSINESSWIRE
Maat Pharma Reports Successful Phase 3 Trial Of Xervyteg
03 Nov 2025 //
BUSINESSWIRE
MaaT Pharma Ph2b PHOEBUS DSMB Review Confirms MaaT033 Safety
07 Oct 2025 //
PHARMIWEB
MaaT Pharma Partners with Clinigen for Xervyteg® in Europe
02 Jul 2025 //
BUSINESSWIRE
MaaT Pharma Presents Results of Annual General Meeting
24 Jun 2025 //
BUSINESSWIRE
MaaT Pharma Submits Marketing Authorization Application for Xervy
02 Jun 2025 //
BUSINESSWIRE
MaaT Pharma to Present Updated Data for MaaT013 at EHA Congress
14 May 2025 //
BUSINESSWIRE
MaaT Pharma Reports First Quarter 2025 Financial Results
13 May 2025 //
BUSINESSWIRE
MaaT Pharma Reports Positive Phase 1b Data for MaaT033 in ALS
12 May 2025 //
BUSINESSWIRE
MaaT Pharma: Positive Safety Interim Analysis for MaaT033 Trial
08 Apr 2025 //
BUSINESSWIRE
MaaT Pharma: Monthly Voting Rights and Share Capital Update
04 Apr 2025 //
BUSINESSWIRE
MaaT Pharma Completes €13M Capital Increase, 2024 Annual Result
27 Mar 2025 //
BUSINESSWIRE
MaaT Pharma Reports Positive DSMB Review For MaaT013
18 Mar 2025 //
BUSINESSWIRE
MaaT Pharma gets positive opinion from EMA on MaaT013 plan
11 Mar 2025 //
BUSINESSWIRE
MaaT Pharma Gets Positive DSMB Review For MaaT033 Allo-HSCT Trial
21 Jan 2025 //
BUSINESSWIRE
MaaT Reports Positive Phase 3 Results For MaaT013 In Graft Disease
08 Jan 2025 //
BUSINESSWIRE
MaaT Pharma Presents Data on MaaT013 in Early Access Program
09 Dec 2024 //
BUSINESSWIRE
MaaT Pharma Presents Positive Data on MaaT013 at ASH 2024
09 Dec 2024 //
BUSINESSWIRE
MaaT Pharma Treats First U.S. Patient at City of Hope for GVHD
05 Dec 2024 //
BUSINESSWIRE
MaaT Pharma Meets ALS Primary Endpoint in Phase 1b Study
26 Nov 2024 //
BUSINESSWIRE
MaaT Pharma Presents Updates from Early Access Program in aGvHD
07 Nov 2024 //
BUSINESSWIRE
MaaT Pharma Q3 2024 Results & Management Changes Announced
05 Nov 2024 //
BUSINESSWIRE
MaaT Pharma Completes Recruitment Of ARES Phase 3 Trial For
15 Oct 2024 //
BUSINESSWIRE
MaaT Pharma Publishes Half Year 2024 Results And Update
19 Sep 2024 //
BUSINESSWIRE
MaaT Pharma to Present and Join Investor and Medical Conferences in September
04 Sep 2024 //
BUSINESSWIRE
MaaT: Positive 18-Month aGvHD Survival For MaaT013
15 Apr 2024 //
BUSINESSWIRE
MaaT Pharma Announces Long Term Follow-Up Data for MaaT013
12 Mar 2024 //
BUSINESSWIRE
MaaT indicates completion of Recruitment for Phase 2a Evaluating MaaT013
05 Mar 2024 //
BUSINESSWIRE
MaaT Pharma Announces Positive Review from Phase 1 Trial Evaluating MaaT033
29 Feb 2024 //
BUSINESSWIRE
MaaT Pharma to Host Virtual KOL Event on MaaT013 and MaaT033
12 Dec 2023 //
BUSINESSWIRE
MaaT Pharma Presents Positive Results with Lead Product MaaT013
11 Dec 2023 //
BUSINESSWIRE
MaaT Pharma Awarded Government Funding for MaaT033
30 Nov 2023 //
BUSINESSWIRE
MaaT Pharma Announces First Patient Dosed in Phase 2b Trial Evaluating MaaT033
06 Nov 2023 //
BUSINESSWIRE
MaaT Pharma Announces Two Poster Presentations for MaaT013 and MaaT033
02 Nov 2023 //
BUSINESSWIRE
MaaT Pharma Announces Positive Outcome in Phase 3 with MaaT013
26 Oct 2023 //
BUSINESSWIRE
MaaT Pharma Announces EMA Granted MaaT033 ODD aiming to improve overall survival
06 Sep 2023 //
BUSINESSWIRE
MaaT Announces Publication of Results in eClinicalMedicine Journal Highlighting Benefit of MaaT013
26 Jul 2023 //
BUSINESSWIRE
MaaT Receives Two Clinical Trial Application Authorizations to Evaluate MaaT033
27 Mar 2023 //
BUSINESSWIRE
